Table 1.
Agent | Mechanism/target | Phase III studies | Phase II studies |
---|---|---|---|
Sipuleucel-T | Autologous cellular immunotherapy – PAP directed | Completed | Combination with abiraterone acetate (NCT01487863); sequencing with androgen ablation (NCT01431391) |
Ipilimumab | Fully human anti-CTLA-4 monoclonal antibody | Prechemo (NCT00861614); postchemo (+ XRT) (NCT01057810) | Neoadjuvant (NCT01194271); combination with androgen ablation (NCT01377389) |
ProstVac-VF | PSA-encoding poxvirus prime/boost regimen | Prechemo (NCT01322490) | Sequencing with docetaxel chemotherapy (NCT01145508); combination with flutamide (NCT00450463) |
pTVG-HP | PAP-encoding DNA vaccine | N/A | Priming doses followed by personalized versus fixed boost regimen (NCT00849121); comparison with GM-CSF (NCT01341652) |
177Lu-J591 | Radiolabeled monoclonal antibody to PSMA | N/A | Combination with Docetaxel (NCT00916123); combination with Ketoconazole in nonmetastatic CRPC (NCT00859781); dose escalation study (NCT00538668) |
CRPC, castration-resistant prostate cancer; CTLA-4, cytotoxic T-lymphocyte-associated antigen-4; GM-CSF, granulocyte macrophage colony-stimulating factor; PAP, prostatic acid phosphatase; PSA, prostate-specific antigen; PSMA, prostate specific membrane antigen; XRT, radiation therapy. For current information, consult www.clinicaltrials.gov.